Senti Biosciences Holdings, Inc. Director Resigns — Compensation Chair

What Happened

• Senti Biosciences Holdings, Inc. (SNTI) announced that director Brenda Cooperstone, Ph.D., notified the Board she resigned from the Board effective immediately on September 23, 2026. She also resigned as a member and Chair of the Board’s Compensation Committee, effective immediately. The company stated her resignation was not due to any disagreement with the company on operations, policies, or practices.

Key Details

• Resignation date: September 23, 2026 (effective immediately).
• Roles vacated: Board member and Chair/member of the Compensation Committee.
• The filing (Form 8‑K) notes no disagreement with the company prompted the resignation.
• The 8‑K was signed by CEO Timothy Lu on September 24, 2026; the filing does not name a replacement.

Why It Matters

• Changes to the Board and committee leadership affect corporate governance and oversight—investors should note the vacancy on the Compensation Committee until a replacement is named.
• The company’s explicit statement that there was no disagreement reduces the likelihood this resignation signals internal disputes; the filing provides no further operational or financial impact.